Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
BSXNegative Net Change DVANegative Net Change ALGNNegative Net Change RMDNegative Net Change
earnings medical medical-devices
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.
REGNNegative Net Change LGNDPositive Net Change ANIPNegative Net Change RARENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change BRKRNegative Net Change
earnings medical medical-devices
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
by Zacks Equity Research
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
LGNDPositive Net Change AGIONegative Net Change ANIPNegative Net Change VYGRNegative Net Change
earnings medical
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change TFXNegative Net Change
earnings medical
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
ALCNegative Net Change GRTSNegative Net Change HIMSNegative Net Change ERASNegative Net Change
earnings-preview earnings-surprise medical
Why Earnings Season Could Be Great for BioNTech (BNTX)
by Zacks Equity Research
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BNTXNegative Net Change
genetic-testing medical
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
SNYPositive Net Change AMRNNegative Net Change ANIPNegative Net Change KYMRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
by Zacks Equity Research
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
LGNDPositive Net Change ANIPNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
4 HMO Stocks to Watch Amid Persistent Industry Challenges
by Debasmita Chatterjee
The Medical-HMO industry continues to witness an expanding customer base resulting from contract wins. However, high technology expenses and a shortage of medical personnel are a concern. UNH, CI, CNC and HUM are likely to navigate industry storms.
UNHPositive Net Change HUMNegative Net Change CIPositive Net Change CNCNegative Net Change
medical
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
ILMNNegative Net Change MEDPNegative Net Change EHCNegative Net Change TMDXNegative Net Change
earnings medical medical-devices
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
by Zacks Equity Research
Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.
AMRNNegative Net Change ANIPNegative Net Change BHCNegative Net Change AMRXPositive Net Change
earnings medical pharmaceuticals
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
TNDMNegative Net Change MEDPNegative Net Change EHCNegative Net Change TMDXNegative Net Change
earnings medical medical-devices
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
by Ritujay Ghosh
Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
RMDNegative Net Change NJRNegative Net Change GWRSPositive Net Change EHCNegative Net Change
medical utilities
Why Krystal Biotech (KRYS) Might Surprise This Earnings Season
by Zacks Equity Research
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
KRYSNegative Net Change
biotechs medical
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
by Zacks Equity Research
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AXSMNegative Net Change
earnings genetic-testing medical
New Strong Buy Stocks for May 3rd
by Zacks Equity Research
MS, NFLX, SIGA, THC and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on May 3, 2023.
MSNegative Net Change NFLXPositive Net Change THCNegative Net Change SIGANegative Net Change TMHCNegative Net Change
consumer-discretionary finance medical
Stock Market News for May 3, 2024
by Zacks Equity Research
U.S. stock markets closed sharply higher on Thursday.
SOPositive Net Change QCOMPositive Net Change BDXNegative Net Change
medical semiconductor utilities
Earnings Season: 3 Companies Boosting Guidance
by Derek Lewis
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.
KOPositive Net Change LLYNegative Net Change ETNPositive Net Change
consumer-staples medical utilities
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change XRAYNegative Net Change
earnings medical medical-devices
Cigna (CI) Q1 Earnings Beat on Client Wins in Evernorth Unit
by Zacks Equity Research
Cigna's (CI) Q1 results reflect strong organic growth in the Evernorth Health Services unit. It expects adjusted EPS of at least $28.40 for 2024, up from the earlier guidance of at least $28.25.
HUMNegative Net Change MOHNegative Net Change CIPositive Net Change CNCNegative Net Change
earnings medical
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
LGNDPositive Net Change ZTSNegative Net Change BPMCPositive Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change ZBHNegative Net Change
earnings medical
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
LGNDPositive Net Change CORTPositive Net Change ANIPNegative Net Change VYGRNegative Net Change
earnings medical
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
JAZZNegative Net Change LGNDPositive Net Change ANIPNegative Net Change VYGRNegative Net Change
earnings medical